AZD 2914

Drug Profile

AZD 2914

Alternative Names: AZD2914

Latest Information Update: 28 Jun 2006

Price : $50

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 08 Jun 2006 Discontinued - Preclinical for Chronic obstructive pulmonary disease in United Kingdom (unspecified route)
  • 27 Jan 2005 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top